Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

Cell Res. 2022 Apr;32(4):404-406. doi: 10.1038/s41422-022-00617-x. Epub 2022 Jan 27.
No abstract available

Publication types

  • Letter

MeSH terms

  • COVID-19 Drug Treatment*
  • Humans
  • Mutation
  • Peptides / pharmacology
  • SARS-CoV-2*

Substances

  • Peptides

Supplementary concepts

  • SARS-CoV-2 variants